Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • NCD 2025
NET Nurse
Donate

Home » News » CommNETS Annual Research Workshop

CommNETS Annual Research Workshop

  • December 8, 2022

NeuroEndocrine Cancer Australia (NECA) CEO, Meredith Cummins attended the annual CommNETs (Commonwealth countries  – Canada, Australia and New Zealand) Research Workshop held  on 30 November to 2 December 2022 in Hawaii.

There were over 30 attendees which included NET multidisciplinary healthcare professionals and Patient Organisations and NECA was thrilled to be part of this meeting.

Many Clinical Trials were discussed, and expressions of interest were made to conduct some of the trials across the 3 countries.

NECA , whilst there, was invited to participate in a CommNETs/NANETS Guidelines Panel over 2 days which will develop guidance documents. Areas which will be researched in literature reviews will be including, however not limited to –

  • Clinical : Tumour grade, Patient age/Presenting Symptoms/comorbidities, Primary site, molecular profile (MGMT loss, MEN1, DAXX, ATRX, p53, RB, transcriptional subtypes), MSI
  • Functional imaging – Dotatate PET, Octreoscan, FDG PET, dual PET, NETPET score
  • Functional markers (e.g. 24h u5HIAA, serum/platelet serotonin, gastrin/VIP, insulin, glucagon), CgA, pancrestatin, NETest

 

From the literature review the document will be reviewed including NET Consumer reviews from each country. The group members were diverse and many differences were acknowledged with regards to health systems and availability / non-availability of investigations, and management of NETs.

“It was such an honour to be invited and NECA is looking forward to the ongoing of these documents and eventually publication” said NECA CEO, Meredith Cummins.

“Group collaboration is the heart of CommNETs, and so much was accomplished this year. It was wonderful to be able to meet face to face and form such strong bonds and networks”.

Plans are in place to hold CommNETs in New Zealand next year following on from AGITG.

 

Share this post

Recent posts

Rare Cancers Roundtable

September 26, 2025

Shining a Light for World Neuroendocrine Cancer Day – Help Us Light Up Australia

September 26, 2025

Celebrating Shane Kent’s Arch2Arc Journey and Fundraising

September 20, 2025

Will Norman Nurse Webinar on Neuroendocrine Cancer

September 19, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousSydney Unicorn Get Together
NextNeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online WillsNext

Related Posts

Rare Cancers Roundtable

NECA recently attended a Rare Cancers Roundtable to discuss “The value of cancer clinical trials and setting up for success.” Attendees were diverse, including industry,

Shining a Light for World Neuroendocrine Cancer Day – Help Us Light Up Australia

Each year on 10 November for World Neuroendocrine Cancer Day, NeuroEndocrine Cancer Australia joins the global movement to raise awareness of Neuroendocrine Tumours (NETs). This

Will Norman Nurse Webinar on Neuroendocrine Cancer

On 17 September, NeuroEndocrine Cancer Australia, NeuroEndocrine UK, and NeuroEndocrine New Zealand came together to deliver the Will Norman Nurse Webinar on Neuroendocrine Cancer. Hosted

13th INCA Global NET Patient Advocate Summit

This week our CEO Meredith Cummins, in her role as President Elect of the INCA Board of Directors and Chair of the Research Committee, presented at

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin